A randomized phase 2 study of irinotecan plus cetuximab with or without enzastaurin in patients with recurrent colorectal cancer.

Trial Profile

A randomized phase 2 study of irinotecan plus cetuximab with or without enzastaurin in patients with recurrent colorectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2010

At a glance

  • Drugs Cetuximab; Enzastaurin; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Jun 2010 Results presented at 12th World Congress on Gastrointestinal Cancer 2010.
    • 26 May 2009 Actual patient number (26) and actual end date (1 May 2009) added as reported by ClinicalTrials.gov.
    • 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top